Compass Therapeutics, Inc. (NASDAQ:CMPX) Shares Purchased by SG Americas Securities LLC

SG Americas Securities LLC raised its holdings in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) by 921.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 395,017 shares of the company’s stock after purchasing an additional 356,352 shares during the period. SG Americas Securities LLC owned about 0.29% of Compass Therapeutics worth $573,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of CMPX. Barclays PLC boosted its position in Compass Therapeutics by 195.4% during the 3rd quarter. Barclays PLC now owns 170,245 shares of the company’s stock valued at $314,000 after purchasing an additional 112,614 shares during the period. Geode Capital Management LLC boosted its position in shares of Compass Therapeutics by 0.8% during the third quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company’s stock worth $4,251,000 after buying an additional 19,095 shares during the period. XTX Topco Ltd bought a new position in Compass Therapeutics in the 3rd quarter worth approximately $37,000. The Manufacturers Life Insurance Company acquired a new stake in Compass Therapeutics in the 3rd quarter valued at approximately $79,000. Finally, Intech Investment Management LLC acquired a new stake in Compass Therapeutics in the 3rd quarter valued at approximately $30,000. 68.43% of the stock is owned by institutional investors and hedge funds.

Compass Therapeutics Trading Up 6.6 %

Shares of Compass Therapeutics stock opened at $3.22 on Friday. Compass Therapeutics, Inc. has a 52 week low of $0.76 and a 52 week high of $3.63. The stock has a market cap of $443.04 million, a PE ratio of -8.70 and a beta of 0.92. The company’s 50-day moving average price is $1.90 and its two-hundred day moving average price is $1.63.

Compass Therapeutics (NASDAQ:CMPX) last released its earnings results on Tuesday, November 12th. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.03. On average, equities analysts predict that Compass Therapeutics, Inc. will post -0.35 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently issued reports on CMPX. Leerink Partnrs cut Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 15th. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Compass Therapeutics in a research report on Wednesday, January 8th. Leerink Partners downgraded shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $5.00 to $4.00 in a research report on Friday, November 15th. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $32.00 price target on shares of Compass Therapeutics in a research note on Wednesday, January 8th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $11.80.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.